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Abstract
Background: Several lines of evidence suggest that chemokines and cytokines play an important
role in the inflammatory development and progression of systemic lupus erythematosus. The aim
of this study was to evaluate the relevance of functional genetic variations of RANTES, IL-8, IL-1α,
and MCP-1 for systemic lupus erythematosus.
Methods: The study was conducted on 500 SLE patients and 481 ethnically matched healthy
controls. Genotyping of polymorphisms in the RANTES, IL-8,  IL-1α, and MCP-1  genes were
performed using a real-time polymerase chain reaction (PCR) system with pre-developed TaqMan
allelic discrimination assay.
Results: No significant differences between SLE patients and healthy controls were observed when
comparing genotype, allele or haplotype frequencies of the RANTES,  IL-8,  IL-1α, and MCP-1
polymorphisms. In addition, no evidence for association with clinical sub-features of SLE was found.
Conclusion: These results suggest that the tested functional variation of RANTES, IL-8, IL-1α, and
MCP-1 genes do not confer a relevant role in the susceptibility or severity of SLE in the Spanish
population.
Background
Systemic lupus erythematosus (SLE) is a chronic and sys-
temic autoimmune disease with a complex pathogenesis
involving multiple genetic and environmental factors. The
disease is characterized by autoantibody production,
abnormalities of immune-inflammatory system function
and inflammatory manifestation in several organs.
Although the pathogenesis of SLE is unknown, the
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increased concordance of SLE in monozygotic versus dizy-
gotic twins and familial clustering provide evidences for
the role of genetic factors in this disorder [1]. However,
the genetic background of SLE is thought to be complex
and involves multiple genes encoding different molecules
with significant functions in the regulation of the immune
system [1-4]. Among the genetic factors believed to influ-
ence susceptibility to SLE, the major histocompatibility
complex (MHC) alleles show the most significant associ-
ation. Importantly, several recent studies show that non-
HLA genes play a role in the development of SLE [1-4]. In
this respect, there are several lines of evidence that chem-
okines and cytokines play an important role in the inflam-
matory development and progression of autoimmune
diseases as SLE [5-7]. Furthermore, it has been show that
SLE patients show an up-regulation of inflammatory mol-
ecules [8,9].
Regulated upon activation, normal T cell expressed and
secreted (RANTES), interleukin 8 (IL-8) and monocyte
chemoattractant protein-1 (MCP-1) are involved in the
physiology and pathophysiology of acute and chronic
inflammatory processes, by recruitment of monocytes, T
lymphocytes and eosinophils to sites of inflammation
[10,11]. Substantial evidence suggest that IL-8 and MCP-
1, contribute to kidney injury in the glomerulonephritis of
SLE, through glomerular leukocyte infiltration [12,13].
Serum levels of these inflammatory chemokines
(RANTES, IL8 and MCP-1) are significantly higher in SLE
patients than in control subjects, and correlated signifi-
cant with SLEDAI score, suggesting a role in the pathogen-
esis of the disease [9]. As a consequence of renal disease,
increased urine MCP-1 and urine IL-8 (uMCP-1, uIL-8)
levels can be detected in SLE patients during active renal
disease [14]. Interestingly some genetic variants within
regulatory regions of these genes can affect the transcrip-
tional activity and subsequent protein expression in
human. For, RANTES the SNPs -403 G/A (rs2107538) and
R3 (rs2306630) T/C, for IL-8 -353 T/A (rs4073) and for
+781 C/T (rs2227306) and MCP-1  -2518 G/A
(rs1024611) have been correlated to mRNA and or pro-
tein expression [15-17].
In addition to these three genes, IL-1α also constitutes a
strong candidate gene for SLE, since it is a proinflamma-
tory cytokine that plays and important role in initiating
and modulating the immune responses. There is a func-
tional polymorphism in the promoter region of IL-1α
gene at position -889 C/T (rs1800587), and the -889 C
homozygous genotype has been associated with signifi-
cantly lower transcriptional activity of the IL-1α gene and
lower levels of IL-1α in plasma compared with the TT gen-
otype [18].
Overall, the chemokines RANTES,  IL-8,  MCP-1and
cytokine  IL-1α  are strong candidate genes for which
genetic association studies can shed light on the underly-
ing mechanisms causing the immune dysregulation, such
as inappropriate T cell activation or trafficking in SLE.
Therefore, the aim of this work was to test for association
of the reported functional polymorphisms in RANTES, IL-
8, MCP-1 and IL-1α with SLE susceptibility.
Methods
Patients
Peripheral blood samples were obtained after written
informed consent from 500 SLE patients meeting the
American College of Rheumatology (ACR) criteria for SLE
[19]. These patients were recruited from five Spanish hos-
pitals: Hospital Virgen de las Nieves and Hospital Clinico
(Granada), Hospital Virgen del Rocio (Seville) and Hospi-
tal Carlos-Haya and Hospital Virgen de la Victoria
(Malaga). Similarly, blood was taken from 481 blood
bank and bone marrow donors of the corresponding cities
that were included as healthy individuals. Both patient
and control groups were of Spanish Caucasian origin and
were matched for age and sex. Eighty seven percent of the
SLE patients were women, the mean age of SLE patients at
diagnosis was 43 ± 13.3 years and the mean age at disease
onset of SLE symptoms was 32 ± 15 years. The SLE clinical
manifestations studied were articular involvement (76%),
renal affectation (37%), cutaneous lesions (62%), hemat-
opoietic alterations (73%), photosensivity (51%), neuro-
logical disease (17%) and serositis (28%). The study was
approved by all local ethical committees from the corre-
sponding hospitals.
Genotyping
For all the considered SNPs, samples were genotyped
using a pre-developed TaqMan allelic discrimination
assay. Table 1 shows the part number and reference of
each SNP (Applied Biosystems, Foster City, CA, USA).
PCR was carried out with mixes consisting of 8 ng of
genomic DNA, 2.5 µl of Taqman master mix, 0.125 µl of
20x assay mix and ddH2O up to 5 µl of final volume. The
following amplification protocol was used: denaturation
at 95°C for 10 min, followed by 40 cycles of denaturation
Table 1: Taqman probes part number used for genotyping.
Polymorphisms Part number
RANTES -403 G/A (rs2107538) C_15874407_10
RANTES R3 C/T (rs2306630) C_26625663_10
IL-8 -353 A/T (rs4073) C_11748116_10
IL-8 +781 C/T (rs2227306) C_11748169_10
IL-1α -889 C/T (rs1800587) C_9546481_20
MCP-1 -2518 G/A (rs1024611) C_2590362_10BMC Medical Genetics 2006, 7:48 http://www.biomedcentral.com/1471-2350/7/48
Page 3 of 8
(page number not for citation purposes)
at 92°C for 15 sec and annealing and extension at 60°C
for 1 min. After PCR, the genotype of each sample was
attributed automatically by measuring the allelic specific
fluorescence on the ABI PRISM 7900 Sequence Detection
Systems using the SDS 2.2.2 software for allelic discrimi-
nation (Applied Biosystems, Foster City, CA, USA).
Statistic analysis
Allele and genotype frequencies were obtained by direct
counting. Hardy-Weinberg equilibrium and statistical
analysis to compare allelic and genotypic distributions
were performed using the chi-square test. Odds ratio (OR)
with 95% confidence intervals (95%CI) were calculated
according to Woolf's method. The software used was Stat-
Calc program (Epi Info 2002; Centers of Disease Control
and Prevention, Atlanta, GA, USA). For the haplotype
analysis, pair-wise linkage disequilibrium measures were
investigated and haplotypes were constructed using the
expectation-maximization (EM) algorithm implemented
in UNPHASED software [20]. P values below 0.05 were
considered statistically significant. The power of the study
to detect an effect of a polymorphism in disease suscepti-
bility was estimated using the Quanto v 0.5 software
(Department of Preventive Medicine University of South-
ern California, CA, USA).
Results
Table 2 shows the allele and genotype distribution of the
RANTES,IL-8, IL-1α, and MCP-1 polymorphisms. For all
polymorphisms, the distribution of genotypes did not
deviate from that expected from populations in Hardy-
Weinberg equilibrium.
RANTES typing
Genotyping of RANTES -403 G/A and R3 T/C was per-
formed in 500 and 442 SLE patients and 481 and 438
healthy controls, respectively (table 2). No statistically sig-
nificant differences were observed when the allele and
genotype distribution was compared between SLE
patients and healthy controls. Also, we found no associa-
tion for the two marker haplotypes (table 3).
IL-8 typing
IL-8 -353 T/A and +781 C/T was genotyping in 439 and
467 SLE patients and 412 and 429 healthy controls,
respectively for each polymorphism. We found a similar
distribution in the allele and genotype frequencies
between SLE patients and controls for both genetic vari-
ants. The haplotype estimation for the -353 T/A and +781
C/T IL-8 polymorphisms revealed a strong degree of link-
age disequilibrium between the two variants (D' = 0.9)
and showed a slight but non-significant increase of the -
353T-+781C haplotype in SLE patients (8.5% vs 6.2%, P
= 0.08, OR = 1.41, 95%CI = 0.94–2.10) (Table 3).
IL-1α typing
IL-1α -889 was typing in 417 SLE patients and 420 healthy
controls. We did not find any significant difference when
allele and genotype frequencies were compared between
SLE patients and healthy controls.
MCP-1 typing
Table 2 show the allele and genotype distribution of the
MCP-1 -2518 A/G polymorphism in 450 SLE patients and
427 controls. No significant differences in the allele and
genotype frequencies of the MCP-1 -2518 A/G polymor-
phism were found between SLE patients and controls.
In addition, available clinical features of patients with SLE
were analysed for possible association with the different
alleles or genotypes of these polymorphisms. When we
stratified SLE patients according to the presence of renal
involvement, no statistically significant differences were
observed in the distribution of RANTES -403, RANTES R3,
IL-1α  -889 and MCP-1  -2518 polymorphisms between
SLE patients with and without lupus nephritis (table 4).
Regarding IL-8 polymorphisms, the AT -353 genotype and
the -353T/+781C haplotype showed an increased among
lupus patients without nephritis compared with patients
with nephritis (39.2% vs 49.4%, P = 0.03, OR = 0.66,
95%CI = 0.44–0.99 for AT -353 genotype) (5.7% vs 10%,
P = 0.05, OR = 0.55, 95%CI = 0.28–1.05 for -353T/+781C
haplotype) (table 4).
Similarly, no significant differences were observed
between all these genetic variants and the following vari-
ables: sex, age at onset, articular involvement, cutaneous
lesions, photosensitivity, hematological alterations, neu-
rological disorders and serositis (data not shown).
Discussion
In this work, we have tested six functional polymorphisms
of four strong candidate genes for association with SLE.
No evidence of association was detected for RANTES (-
403 G/A, R3 T/C),IL-8  (-353 A/T, +781 C/T), IL-1α  (-
889C/T), and MCP-1 (-2518 G/A) polymorphisms. How-
ever, a significant association was observed for the IL-8
haplotype with SLE nephritis, which cannot be considered
as significant after correction for multiple comparisons.
All these genes have been previously associated with sus-
ceptibility and development to several autoimmune dis-
orders, included SLE [16,21-27]. For example, recent
studies in Asian populations found another RANTES pol-
ymorphism (-28C/G) to be associated with increased risk
of developing SLE, but failed to detect any association of
RANTES -403 polymorphisms with SLE [22,23]. We did
not test the -28C/G variant as -28G allele is relatively
uncommon in Caucasians [28].BMC Medical Genetics 2006, 7:48 http://www.biomedcentral.com/1471-2350/7/48
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Table 2: Allele and genotype frequencies of RANTES, IL-8, MCP-1 and IL-1α polymorphisms in SLE patients and healthy controls.
SLE patients Controls P OR (95%CI)
RANTES -403 n % n %
Genotypes
GG 369 73.8 333 69.3 0.1
GA 113 22.6 135 28 0.04 0.75 (0.55–1.01)
AA 18 3.6 13 2.7 0.4
Alleles
G 851 85 801 83.3
A 149 15 161 16.7 0.2
RANTES R3 n % n %
Genotypes
CC 326 73.8 340 77.6 0.06
CT 104 23.5 90 20.6 0.3
TT 12 2.7 8 1.8 0.4
Alleles
C 756 85.5 770 88
T 128 14.5 106 12 0.1
IL-8 -353 n % n %
Genoypes
AA 126 28.7 125 30.3 0.6
AT 215 49 194 47.1 0.5
TT 98 22.3 93 22.6 0.9
Alleles
A 467 53.2 444 53.8
T 411 46.8 380 46.2 0.7
IL-8 +781 n % n %
Genotypes
CC 164 35 143 33.3 0.6
CT 238 51 221 51.5 0.8
TT 65 14 65 15.2 0.6
Alleles
C 566 60.6 507 59.1
T 368 39.4 351 40.9 0.5
IL-1α -889 n % n %
Genotypes
CC 220 52.7 209 49.7 0.4
CT 164 39.3 166 39.5 0.9
TT 33 7.9 45 10.7 0.2
Alleles
C 604 72.4 584 69.5
T 230 27.6 256 30.5 0.2
MCP-1 -2518 n % n %
Genotypes
AA 238 57.2 250 58.5 0.6
AG 173 35 154 36 0.7
GG 39 7.8 23 5.4 0.1
Alleles
A 739 74.6 654 76.6
G 251 25.4 200 23.4 0.3BMC Medical Genetics 2006, 7:48 http://www.biomedcentral.com/1471-2350/7/48
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The genetic variant IL-8 -845C showed a high association
to severe lupus nephritis (LN) in an African American
population [16], but also this allele has a very low fre-
quency in Caucasian populations [16,29]. The trend of
association that we have found between the haplotypes
and LN and the reported association of other IL-8 variants
this African American population, shows that variants in
this chemokine may have a minor influence on the risk of
developing nephritis in SLE patients.
Similar observation could be made for the reported asso-
ciation of the IL-1α -889C/T variant to SLE in a White and
African American populations from United States, which
we failed to replicate [30]. With regard to the MCP-1 -
2518 polymorphism, an American study showed that an
A/G or G/G genotype may predispose to the development
of SLE and further indicated that SLE patients with these
genotypes may be at higher risk of developing LN [3].
The fact that we do not observe an association and fail to
confirm some previous studies may be caused by a Type II
error (false-negative). This is however unlikely because
our sample has more than 80% power to detect the rela-
tive risk similar to the other studies at the 5% significance
level. Furthermore, the genotype frequencies did not dif-
fer from Hardy-Weinberg expectations, and allele and
genotype frequencies in our Spanish population are simi-
lar to those reported previously in other Caucasian popu-
lations [16,26,31,32]. The failure to replicate reported
associations is a common event in the search for genetic
determinants of complex diseases, due either to genuine
population heterogeneity or a different sort of bias [33].
The lack of replication in our population may alterna-
tively be explained by a different racial composition of
that study from ours, or that presence of environmental
factors to which the Asian, American, and African popula-
tions, but not the Spanish population, are exposed. In
addition, genetic differences are known to exist between
the different ethnic groups, such as, African American and
Caucasians.
Conclusion
In conclusion, our results suggest that functional genetics
variation in RANTES, IL-8, IL-1α, and MCP-1 do not play
a major role in SLE susceptibility in the Spanish popula-
tion.
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Table 3: Haplotype frequencies for RANTES and IL-8 polymorphisms in SLE patients and controls.
Gene Haplotype SLE patients Healthy controls Pvalue OR (95%CI)
RANTES
-403A/R3C 25 (5.7) 25 (5.8) ns
-403A/R3T 50 (11.3) 40 (9.3) ns
-403G/R3C 355 (80.7) 356 (83.4) ns
-403G/R3T 10 (2.3) 6 (1.5) ns
IL-8
-353T/+781C 69 (8.6) 48 (6.2) 0.08 1.41 (0.94–2.10)
-353T/+781T 316 (39.2) 303 (39.4) ns
-353A/+781C 403 (50) 406 (52.7) ns
-353A/+781T 18 (2.2) 13 (1.7) nsBMC Medical Genetics 2006, 7:48 http://www.biomedcentral.com/1471-2350/7/48
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Table 4: Relationship between RANTES, IL-8, MCP-1 and IL-1α polymorphisms and the presence of nephritis in SLE Spanish patients.
SLE with nephritis SLE without nephritis P OR (95%CI)
RANTES - 4 0 3 n%n%
Genotypes
GG 136 73.5 230 73 0.9
GA 44 23.8 71 22.5 0.7
AA 5 2.7 14 4.4 0.3
Alleles
G 5 41 4 . 69 91 5 . 7
A 316 85.4 531 84.3 0.6
RANTES R 3 n%n%
Genotypes
CC 89 77.4 225 68.8 0.08
CT 23 20 92 28.1 0.1
TT 3 2.6 10 3 0.8
Alleles
C 201 87.4 542 82.9
T 29 12.6 112 12.1 0.1
IL-8 - 3 5 3 n%n%
Genoypes
AA 47 26.7 59 22.4 0.3
AT 69 39.2 130 49.4 0.03 0.66 (0.44–0.99)
TT 60 34.1 74 28.2 0.2
Alleles
A 163 46.3 248 47.2
T 189 53.7 278 52.8 0.8
IL-8 + 7 8 1 n%n%
Genotypes
CC 74 39.6 99 35.3 0.3
CT 85 45.4 151 54 0.07
TT 28 15 30 10.7 0.2
Alleles
C 233 62.3 349 62.3
T 141 37.7 211 37.7 0.9
IL8 -353T/+781C
Haplotypes
-353T/+781C 15 5.7 39 10 0.05 0.55 (0.21–8.05)
-353T/+781T 104 39.7 149 38.2 0.7
-353A/+781C 140 53.4 193 49.5 0.3
-353A/+781T 3 1.2 9 2.3 0.3
IL-1α -889
Genotypes
CC 72 49.3 138 50.9 0.7
CT 59 40.4 115 42.4 0.7
TT 15 10.3 18 6.7 0.2
Alleles
C 203 69.5 391 72.1
T 89 30.5 151 27.9 0.4BMC Medical Genetics 2006, 7:48 http://www.biomedcentral.com/1471-2350/7/48
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